Mabwell's incubated firm, SynuSight Biotech, has secured NMPA approval to conduct Phase I trials for its promising α-syn PET tracer, SST001.

SynuSight Biotech's groundbreaking collaboration with Shanghai Jiao Tong University has unveiled a novel diagnostic method for synucleinopathies, enhancing clinical classifications and detection.

SHANGHAI, April 15, 2026 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that 18F-FD4 (R&D code: SST001), an α-synuclein (α-syn) targeted PET tracer independently developed by its incubated company SynuSight Biotech, has recently been approved by the National Medical Products Administration (NMPA) to initiate a Phase I clinical […]

A strategic partnership among SynuSight Biotech, ABLi Therapeutics, and XingImaging aims to enhance clinical trials of risvodetinib through advanced imaging techniques for Parkinson's disease.

XingImaging has partnered with SynuSight to develop a PET tracer for Parkinson’s disease, supported by a $3.84M grant from The Michael J. Fox Foundation.

Developing disease-modifying therapies for Parkinson's and related neurodegenerative diseases through targeting Abelson Tyrosine Kinases.

SHANGHAI, May 27, 2026 /PRNewswire/ -- SynuSight Biotech (SynuSight), a clinical-stage biotech company focused on innovative pipeline development for neurodegenerative diseases, today announced the publication of a collaborative study in Cell with Professor Dan Li's team at the Bio-X...

SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI, ATLANTA and NEW HAVEN, Conn. , Jan. 5, 2026 /PRNewswire/ -- SynuSight Biotech ("SynuSight"), a biotechnology...